Phase i study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors

Matthew Zibelman, Yu Ning Wong, Karthik Devarajan, Lois Malizzia, Alycia Corrigan, Anthony J. Olszanski, Crystal S. Denlinger, Susan Roethke, Colleen H. Tetzlaff, Elizabeth R. Plimack

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Fingerprint

Dive into the research topics of 'Phase i study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science